Viking Therapeutics Inc
NASDAQ:VKTX
Viking Therapeutics Inc
NASDAQ:VKTX
Price:
32.83
USD
4.19%
Market Closed
Market Cap:
$3.7B
Balance Sheet
Balance Sheet Decomposition
Viking Therapeutics Inc
Viking Therapeutics Inc
Balance Sheet Decomposition is not available for
Viking Therapeutics Inc
Viking Therapeutics Inc
Balance Sheet
Viking Therapeutics Inc
Viking Therapeutics Inc
Currency: USD
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
1
|
1
|
3
|
9
|
25
|
8
|
29
|
26
|
37
|
56
|
27
|
166
|
|
| Cash |
0
|
0
|
1
|
1
|
3
|
9
|
25
|
8
|
29
|
26
|
37
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
56
|
27
|
166
|
|
| Short-Term Investments |
0
|
0
|
0
|
13
|
10
|
12
|
277
|
267
|
219
|
176
|
119
|
307
|
876
|
540
|
|
| Other Current Assets |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
8
|
8
|
8
|
12
|
5
|
5
|
10
|
|
| Total Current Assets |
0
|
0
|
1
|
15
|
14
|
22
|
302
|
284
|
256
|
211
|
167
|
367
|
907
|
716
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
2
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
0
N/A
|
3
+1 400%
|
15
+413%
|
15
-6%
|
22
+52%
|
302
+1 268%
|
284
-6%
|
257
-10%
|
211
-18%
|
169
-20%
|
368
+119%
|
908
+146%
|
716
-21%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
0
|
0
|
2
|
1
|
1
|
2
|
1
|
2
|
4
|
1
|
9
|
8
|
10
|
53
|
|
| Accrued Liabilities |
0
|
0
|
20
|
1
|
1
|
2
|
4
|
4
|
8
|
7
|
13
|
12
|
18
|
23
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
3
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
0
|
0
|
23
|
2
|
7
|
9
|
5
|
7
|
12
|
9
|
22
|
19
|
27
|
77
|
|
| Long-Term Debt |
0
|
0
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
1
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
|
| Total Liabilities |
0
N/A
|
0
+300%
|
25
+6 200%
|
7
-73%
|
7
-3%
|
9
+34%
|
5
-47%
|
7
+54%
|
12
+72%
|
9
-28%
|
23
+164%
|
20
-13%
|
28
+40%
|
77
+173%
|
|
| Equity | |||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
0
|
0
|
22
|
46
|
60
|
81
|
103
|
129
|
168
|
223
|
292
|
378
|
488
|
848
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
54
|
68
|
94
|
401
|
406
|
413
|
426
|
445
|
734
|
1 369
|
1 486
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
7
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
0
|
|
| Total Equity |
0
N/A
|
0
-200%
|
22
-7 267%
|
9
N/A
|
8
-8%
|
14
+69%
|
298
+2 106%
|
277
-7%
|
244
-12%
|
202
-17%
|
145
-28%
|
348
+140%
|
880
+153%
|
639
-27%
|
|
| Total Liabilities & Equity |
0
N/A
|
0
N/A
|
3
+1 400%
|
15
+413%
|
15
-6%
|
22
+52%
|
302
+1 268%
|
284
-6%
|
257
-10%
|
211
-18%
|
169
-20%
|
368
+119%
|
908
+146%
|
716
-21%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
9
|
9
|
9
|
10
|
21
|
36
|
72
|
72
|
73
|
78
|
78
|
100
|
112
|
115
|
|
Switch to:
Switch to:
See Also
Discover More
